Modulation of CD8+ T Cell Responses by HLA-F

HLA-F 对 CD8 T 细胞反应的调节

基本信息

  • 批准号:
    10366075
  • 负责人:
  • 金额:
    $ 23.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-09 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

CD8+ T cells are critical for clearance of viral-infected cells and tumor cells. They recognize antigens presented by human leukocyte antigen class I (HLA-I) molecules. HLA-F is a non-classical HLA-I molecule that has recently been drawing a lot of attention due to its potential significance in several viral infections and cancers. Although HLA-F was previously believed to be expressed only as open conformers (without peptide), recent studies showed that HLA-F can also be expressed as peptide-associated form. Due to its limited polymorphisms, HLA-F is an attractive target for viral infection control and cancer immunotherapy. However, it is still not clear whether and how HLA-F modulates the function of CD8+ T cells. In this proposal, we expect to address the function of HLA-F in CD8+ T cell responses with the following specific aims: Aim 1: Determine the HLA-F antigen presentation pathway. Both of the accumulation in the endoplasmic reticulum (ER) and the open conformation on the cell surface indicate peptide loading of HLA-F in the ER is inefficient. Our preliminary study suggests an unconventional antigen presentation pathway. We will determine where and how peptides are loaded to HLA-F, which will facilitate the future vaccine design. Aim 2: Determine the effect of HLA-F on CD8+ T cell activation. HLA-F specific CD8+ T cells will be isolated from peripheral blood of pathogen-experienced donors. The isolated CTLs will be used to investigate how HLA-F presents peptides to CTL. Since HLA-F is predominantly expressed as open conformers, we will also determine the effect of HLA-F open conformers on CD8+ T cell activation. Successful completion of this proposal will reveal the antigen presentation mechanisms of HLA-F and how HLA-F modulates CD8+ T cell responses, contributing to developing HLA-F based immunotherapies.
CD 8 + T细胞对于清除病毒感染的细胞和肿瘤细胞至关重要。它们识别抗原 人类白细胞抗原I类(HLA-I)分子。HLA-F是一种非经典的HLA-I分子, 最近由于其在几种病毒感染和癌症中的潜在意义而引起了很多关注。 虽然以前认为HLA-F仅表达为开放构象异构体(无肽),但最近发现, 研究表明,HLA-F也可以表达为肽相关形式。由于其有限 由于HLA-F基因多态性,HLA-F是病毒感染控制和癌症免疫治疗的有吸引力的靶标。但 目前尚不清楚HLA-F是否以及如何调节CD 8 + T细胞的功能。 在本提案中,我们期望通过以下方式来解决HLA-F在CD 8 + T细胞应答中的功能 具体目的:目的1:确定HLA-F抗原呈递途径。两种积累在 内质网(ER)和细胞表面上的开放构象表明HLA-F的肽负载, ER效率低下。我们的初步研究表明,一个非常规的抗原呈递途径。我们将 确定肽在哪里以及如何加载到HLA-F,这将有助于未来的疫苗设计。目标二: 确定HLA-F对CD 8 + T细胞活化的影响。HLA-F特异性CD 8 + T细胞将从以下分离: 有病原体经验的供体的外周血。分离的CTL将用于研究HLA-F 向CTL呈递肽。由于HLA-F主要表达为开放构象,我们还将 确定HLA-F开放构象异构体对CD 8 + T细胞活化的影响。 成功完成这一建议将揭示HLA-F的抗原提呈机制,以及如何 HLA-F调节CD 8 + T细胞应答,有助于开发基于HLA-F的免疫疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jie Geng其他文献

Jie Geng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jie Geng', 18)}}的其他基金

Modulation of CD8+ T Cell Responses by HLA-F
HLA-F 对 CD8 T 细胞反应的调节
  • 批准号:
    10190617
  • 财政年份:
    2021
  • 资助金额:
    $ 23.4万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 23.4万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了